Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Alerting Network Dysfunction in Early Multiple Sclerosis.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Cladribine
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Cyclophosphamide
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Mitoxantrone for multiple sclerosis.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Ofatumumab Dose-finding in RRMS Patients
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Pages